Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma
Mrinal M. Gounder(Memorial Sloan Kettering Cancer Center), Albiruni Ryan Abdul Razak(Roche (Switzerland)), Sharon Friedlander(Roche (Switzerland)), Jean‐Richard Saint‐Martin(Roche (Switzerland)), William D. Tap(Memorial Sloan Kettering Cancer Center), Herbert H. Loong(Memorial Sloan Kettering Cancer Center), Thaddeus J. Unger(Roche (Switzerland)), Kjirsten Nyquist-Schultz(Roche (Switzerland)), Abha A. Gupta(Roche (Switzerland)), Mark A. Dickson(Memorial Sloan Kettering Cancer Center), Joseph P. Erinjeri(Memorial Sloan Kettering Cancer Center), Mercedes M. Condy(Roche (Switzerland)), Sharon Shacham(Roche (Switzerland)), Lanier R. Tanner(Roche (Switzerland)), Samer Salah(Roche (Switzerland)), Alona Zer(Rambam Health Care Campus), Mary Louise Keohan(Roche (Switzerland)), Tami Rashal(Roche (Switzerland)), Sandra P. D’Angelo(Memorial Sloan Kettering Cancer Center), Joel Ellis(Roche (Switzerland)), Robert Carlson(Roche (Switzerland)), S. Baker(Roche (Switzerland)), Jasmine H. Francis(Memorial Sloan Kettering Cancer Center), Michael Kauffman(Roche (Switzerland)), Gary K. Schwartz(Baylor University Medical Center)
Cited by 165
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
|The Lancet Oncology|2019|1.7k
Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry
|Journal of Clinical Oncology|2005|1.1k